Natural history of recurrent hepatitis C.

PubWeight™: 1.49‹?› | Rank: Top 4%

🔗 View Article (PMID 12362293)

Published in Liver Transpl on October 01, 2002


Marina Berenguer1

Author Affiliations

1: Hepato-Gastroenterology Service, La Fe Hospital, Valencia, Spain.

Articles citing this

Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61

Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest (2009) 1.65

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog (2006) 1.09

Tools enabling the elucidation of molecular pathways active in human disease: application to Hepatitis C virus infection. BMC Bioinformatics (2005) 0.95

Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol (2004) 0.91

Living-donor liver transplantation and hepatitis C. HPB Surg (2013) 0.90

Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant (2015) 0.88

Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87

Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation (2012) 0.87

The management of patients awaiting liver transplantation. Nat Rev Gastroenterol Hepatol (2009) 0.86

Long-term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc (2012) 0.86

SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85

Barriers preventing liver transplantation in Canadians with HIV-infection--perceptions of HIV specialists. Can J Gastroenterol (2007) 0.84

Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83

Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin. Antimicrob Agents Chemother (2005) 0.83

New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83

Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. PLoS One (2013) 0.81

Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol (2014) 0.81

Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79

Determining major genotypes of hepatitis C virus among transplant recipients by real-time polymerase chain reaction assay. Jundishapur J Microbiol (2015) 0.79

NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int (2007) 0.79

Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci (2009) 0.78

Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy. World J Gastroenterol (2013) 0.77

Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol (2005) 0.76

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol (2017) 0.75

Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation. Mem Inst Oswaldo Cruz (2015) 0.75

Clinical management of patients with recurrent viral hepatitis after liver transplantation. J Ultrasound (2007) 0.75

Antihepatitis C virus therapy in liver transplanted patients. Ther Clin Risk Manag (2006) 0.75

Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World J Gastroenterol (2016) 0.75

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients. Can J Gastroenterol Hepatol (2016) 0.75

Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr (2016) 0.75

Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. J Clin Transl Hepatol (2016) 0.75

Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation. J Gastroenterol (2007) 0.75

Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75

Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance. J Transplant (2009) 0.75

Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. Eur J Clin Pharmacol (2015) 0.75

Renoportal anastomosis in right lobe living donor liver transplantation: report of a case. Surg Today (2012) 0.75